Roche announces positive results from two pivotal studies of alectinib which shrank tumours with specific type of lung cancer

… advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC) whose disease had progressed … half of people with ALK-positive lung cancer, and these studies suggest that … for people whose advanced ALK-positive lung cancer progressed on crizotinib.” Results from …